Intrepid Family Office’s C4 Therapeutics CCCC Stock Holding History

Intrepid Family Office’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$304K	Buy	65,000 +5,000	+8%	+$17.1K	0.22%	32
2026 Q1	$158K	Buy	60,000 +5,000	+9%	+$11.8K	0.13%	35
2025 Q4	$105K	Sell	55,000 -15,000	-21%	-$35.5K	0.09%	34
2025 Q3	$155K	Buy	70,000 +30,000	+75%	+$72K	0.13%	34
2025 Q2	$57.2K	Hold	40,000	–	–	0.05%	38
2025 Q1	$64K	Hold	40,000	–	–	0.09%	30
2024 Q4	$144K	Buy	+40,000	New	+$199K	0.15%	32

Other funds holding CCCC

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $322M AUM

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Intrepid Family Office's CCCC Position: Q2 2026 in Review

Intrepid Family Office increased its C4 Therapeutics (CCCC) stake by 8.3% in Q2 2026, buying an estimated $17.1K and bringing the position to 65,000 shares worth $304K. The position accounts for 0.22% of the portfolio, ranked #32.

Intrepid Family Office first reported a position in CCCC in Q4 2024 and has held it in 7 quarters since. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

Intrepid Family Office held 65,000 shares of C4 Therapeutics worth $304K as of Q2 2026.
Intrepid Family Office bought 5,000 C4 Therapeutics shares in Q2 2026, an estimated $17.1K.
C4 Therapeutics made up 0.22% of Intrepid Family Office's portfolio in Q2 2026, its #32 holding.
Intrepid Family Office first reported a position in C4 Therapeutics in Q4 2024 and has held it in 7 quarters since.
148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Intrepid Family Office's 13F filing for Q2 2026, filed 14 Aug 2026.